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Medication non-adherence after solid organ transplantation is prevalent, with approximately 25% of transplant recipients not taking their medications as prescribed.  Immunosuppression non-adherence leads to significant public health implications including transplanted organ failure, death, and increased patient and health system costs.  Furthermore, more patients die on the organ transplant waiting list each year due to the scarcity of donated organs.  Thus, it is critical for healthcare professionals to empower and educate transplant recipients to serve as the primary stakeholders in their medical care. A pressing challenge to optimal medication adherence after transplantation is due to a large burden of immunosuppression and anti-infection medicines. Furthermore, post-transplant medication regimens are complex and require patients to be precise with dosing times.  Due to this complexity, delaying a dose by several hours can lead to detrimental clinical outcomes.  Additionally, there have been numerous social and physical determinants linked to non-adherence with immunosuppression regimens.  Research using validated scales or methods involving the measurement of immunosuppression adherence after transplantation is also scarce.  Furthermore, effective interventional methods to improve medication adherence after transplantation have been largely absent.  Successful interventions on immunosuppression adherence should not only educate patients, but also incorporate behavioral change to provide a lasting effect.  
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The National health care expenditure (NHE) in the United States continues to be a large component of the nation’s Gross Domestic Product (GDP), accounting for 17.8% of total GDP.  The NHE of $3.2 trillion or $9,990 per person is growing at an alarming rate; increasing 5.8% in 2015 from the previous year.  Projections out to the year 2020 illustrate that health care expenditures will continue to rise and account for 20% of GDP. Additionally, the majority (62%) of the NHE can be divided into hospital care, physician and clinical services, and retail prescription drugs.1-3 Thus, these statistics demonstrate the urgent need to bring these costs within a suitable and more sustainable range.  One of the options to reduce health care expenditures is to decrease wasteful and ineffective patient care as the lowest available estimates show that this spending accounts for over 20% of all the dollars spent on U.S. health care.4 Wasteful and avoidable spending is an obvious source of health care costs to eliminate rather than cutting funding to other patient care-related endeavors.  The Affordable Care Act (ACA) addresses wasteful spending through value-based purchasing as it encourages physicians and hospitals to reduce patient injury, adopt best evidence-based practices, and avoid ineffective care.  
Medication non-adherence is a large contributor to avoidable healthcare costs accounting for $100 to $300 billion of preventable health care expenditures.5,6 From a public health standpoint, non-adherence is a large concern not only due to its cost impact on the U.S. health care system, but also because non-adherence is estimated to contribute to approximately 125,000 deaths per year.7  Furthermore, 33 to 69% of all medication-related hospital admissions are due to poor medication adherence.8 The prevalence of medication non-adherence is also staggering.  The level of medication non-adherence in clinical trials are known to be falsely elevated; however, even these rates are only reported to be between 22 to 57%.9  These non-adherence statistics are based on patients from the general population rather than all patients with high complexity medication regimens.  
Solid organ transplant recipients are presented with life-sustaining immunosuppression regimens after transplantation.  These medications are essential; however, they represent a large challenge to patients due to the complexity of their timing and high pill burden.  The purpose of this review is to assess the prevalence and impact of medication non-adherence after transplantation, define available medication adherence monitoring tools, and to propose a program to strengthen medication adherence assessment after solid organ transplantation.11
1.1	MEDICATION BURDEN after Transplantation
Solid organ transplantation represents a life-saving treatment options for various patient suffering for end-stage organ diseases.  In fact, a study of the United Network for Organ Sharing (UNOS) database by Rana et al10 demonstrated that solid organ transplantation has saved 2,270,859 life-years over a 25-year period from 1987 to 2012.  This equates to 4.3 life-years saved per solid organ transplant recipient versus those individuals remaining on the waiting list.   Much of the success observed within the field of transplantation is due to the significant advances in immunosuppression.11  With the advent of cyclosporine in the 1980s and the development of tacrolimus in the 1990s, this new class of medications called calcineurin inhibitors revolutionized the short- and long-term outcomes after solid organ transplantation.  The calcineurin inhibitors, tacrolimus and cyclosporine, work at the intracellular level of lymphocytes by binding to calcineurin and preventing the dephosphorylation of the nuclear factor of activated T cells.  This inhibition pathway ultimately halts the production of interleukin-2; an essential lymphokine for the expansion of T cells.11  Unfortunately, calcineurin inhibitors possess a narrow therapeutic index and require therapeutic drug monitoring (TDM) in order to optimize clinical outcomes after transplantation.12  The pharmacokinetics of calcineurin inhibitors are complex and are associated with high inter- and intra-patient variability.  Additionally, these medications are affected by various metabolic and receptor genotypes and phenotypes leading to highly variable pharmacokinetic and pharmacodynamic profiles.  Genotypic variation in calcineurin inhibitor pharmacokinetics is caused by individual variation in cytochrome P450 (CYP 450) enzymes and p-glycoprotein (P-gp) efflux pumps.11,12    P-gp gentic variations can significantly alter the amount of calcineurin inhibitors that reach systemic circulation in the blood.  Furthermore, genetic variation in P-gp affects the exposure from calcineurin inhibitors in lymphocytes.12  A study by Debette-Gratien et al13 demonstrated that genotypic variation in ABCB1, the gene that controls transcription of P-gp, can lead to increased risk of chronic rejection after liver transplantation.  Although genotypic variation in these enzymes is known, long-term outcomes have not shown significant improvement by genotyping prior to transplantation.11-14  Nonetheless, these medications must be individualized based on case-by-case basis as they are not a one-size-fits-all dose.14  In order to optimize medication-related outcomes with calcineurin inhibitors, a complex therapeutic plan and a high degree of adherence from a patient and healthcare provider are required.  After hospital discharge, transplant recipients are instructed to take their calcineurin inhibitors at the same time of the day every day and adhere to a strict monitoring regimen in which frequent visits to the hospital or clinic setting for blood samples are required.  Slight deviations in medication administration timing by the patient can drastically skew trough level results.12  
The burden of post-transplant medications is also not solely based on the complexity of dosing calcineurin inhibitors.  Immunosuppression strategies after transplant are typically multimodal, meaning that, multiple agents are employed to act at unique intracellular targets or cell-surface receptors.14  Although a multimodal regimen is more effective than single-agent therapy alone, it adds to the level of complexity and medication burden after transplantation.  Figure 1. demonstrates how immunosuppressive agents are used in combination after solid organ transplantation.  


Figure 1. Multimodal immunosuppression strategies after solid organ transplantation
1.2	Social determinants impacting Immunosuppression ADHERENCE
The social determinants of public health as outlined by Healthy People 2020 describes the environment and conditions individuals are regularly exposed to that contribute to quality-of-life, functioning, and health outcomes.16  These determinants can also be used to understand the factors that contribute to non-adherence after solid organ transplantation.  As an example, patient economic stability is a critical factor in the access of post transplantation medications.  Transplantation is considered a chronic disease state after the initial procedure because patients are maintained on life-long immunosuppression.  Immunosuppression is costly over time depending on the specific regimen and needs of the patient.  Additionally, transplantation can inhibit a patient’s functional status and ability to generate income for a long period of time after their surgery.  A study by Genao et al.17 demonstrates that lung transplant recipients have a decline in Karnofsky Performance Score (KPS) as they move further out from transplantation.  Furthermore, this effect was consistently observed even when stratifying groups by age.  In the United States, patients with low-income or no insurance have been consistently shown to have worse adherence versus those who are covered by insurance or have high income.18-21  A strong effort is typically made to ensure that a patient has adequate resources prior to their transplantation.  However, their economic and insurance structures can change drastically after the completion of their transplantation.  It is critical that the pre-transplant evaluation phase is multidisciplinary to include social workers in order to assess financial stability both before and after transplantation.  
Education level has also been implicated in numerous studies evaluating medication adherence with mixed results.  In a study by Yavuz et al22, investigators concluded that adherence with immunosuppression medications increased numerically and trended toward significance (p=0.059) with increasing education level.  Interestingly, this finding is in contrast with a study conducted in 141 transplant patients comprised of heart, liver, and lung recipients.23 On multivariable analysis, education level higher than 12th grade was associated with a 2.7 [OR 2.7 95% CI 1.16-6.61] times higher likelihood of non-adherence versus a recipient who had a 12th grade education or less.  Plausible explanations for this phenomenon are that recipients who possess higher level education are busier with work schedules.  This results in patients who are less likely to take their medication.24,25  Additionally, it has been postulated that patients with higher education are more independent and decisive in their medical care.  This leads to patients taking charge and making decisions as to not use certain medications or therapies that the individual may deem harmful or ineffective.26 It is clear that education does play a role in determining one’s medication adherence after transplantation, however; more investigations should be conducted to determine its direction of impact.  
Social support appears to be another contributor to medication adherence after solid organ transplantation.  For patients to be successful with their complex immunosuppression regimens, they require a strong social support via family or a spousal partner if they are unable to manage their medication regimens individually.  Marital status or patients who have a consistent support from significant others have been shown to be at less risk for medication nonadherence.27-31  A study of solid organ transplant recipients displayed that having strong social support after transplantation significantly reduced the likelihood of medication nonadherence [OR 0.94 95% CI 0.89-0.99].23
The healthcare system and healthcare providers operating within them also play a role in medication adherence.  Physicians who have poor communication techniques are more likely to confuse and frustrate patients into becoming non-adherent with medication and treatment regiments.  Evidence has shown that physicians who are supportive emotionally towards patients and reassure that adhering to medication regimens is in their best interest results in improved adherences. It is also important for physicians to treat patients as if they are a partner in their medication treatment.31  This provides empowerment to the patient and transfers a sense of responsibility.29 Accessibility and proximity to healthcare facilities can also be an integral component to immunosuppression nonadherence.31 Solid organ transplant recipients are often affected with comorbidities such as renal disease, diabetes, hypertension, hyperlipidemia, and cardiovascular complications.  These complications can lead solid organ transplant recipients to see numerous specialists along with their primary care physician.  This becomes a constant struggle for both patients and physicians regarding medical treatment for a number of disease states.  For instance, a patient may not understand which physician they need to see in order to have a specific problem assessed.31  
1.3	PHYSICAL DETERMINANTS IMPACTING IMMUNOSUPPRESSION ADHERENCE
Transplant recipient age has been studied extensively as a predictor of medication-related adherence after transplantation.  In a study conducted by Greenstein et al,32 every year in age increase was associated with a 1.6 increase [OR 1.6 95% CI 1.38-1.78] in the likelihood of immunosuppression adherence.  Other studies have also found similar findings that older age is associated with better adherence.33,43  Additionally, Pinsky et al.33 demonstrated that kidney transplant recipients from 19 to 24 years of age were at higher risk for persistent non-adherence versus those between the ages of 25 to 44 years of age.  




Figure 2. Social and physical determinant model of immunosuppression noncompliance after transplantation


1.4	CLINICAL OUTCOMES IN SOLID ORGAN TRANSPLANTATION RESULTING FROM IMMUNOSUPPRESSION NONADHERENCE
	After transplantation, immunosuppression regimens need to be strictly adhered to in order to prevent rejection.  This is especially important in the early post-transplant period (<6 months) when the risk of rejection is at its greatest.37,38  Naturally, medication adherence is thought to be critical throughout all periods of the post-transplantation period, but the relationship between non-adherence and acute cellular rejection (ACR), transplanted graft loss, and mortality has been difficult to characterize.  Quantification of medication adherence is difficult to measure because there is no established method.  Thus, many clinical studies measure adherence in different ways.39 Furthermore, transplant candidates may be identified in the pre-transplantation period as being nonadherent.  Is this a direct contraindication to transplantation or can these patients be intervened on to prevent nonadherence post transplantation?  These are dilemmas that transplant programs must consider.   




Table 1. Studies reporting the impact of immunosuppression nonadherence on graft loss after kidney transplantation

Authors	Number of non-adherent transplant recipientsN (%)	Odds ratio of graft loss in nonadherent vs. adherent groupsOR (95% CI)
Didlake et al.29	25 (4.7)	5.2 (2.3-11.8)
Schweizer et al.37	47 (18.0)	14.5 (6.8-30.6)
Lai et al.40	11 (4.8)	20.9 (5.0-88.4)
Butkus et al.41	10 (10.0)	31.4 (1.8-551.8)
Kalil et al.42	4 (2.0)	4.5 (0.7-26.7)
Kiley et al.43	56 (53.3)	3.4 (1.0-11.9)
Douglas et al.44	60 (47.6)	3.7 (1.7-8.4)
Butkus et al.45 (2001)	10 (7.8)	4.5 (1.3-16.2)
*Adapted from Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004; 77: 769-789.  


	Although there is much less data linking outcomes to poor medication adherence after lung transplantation versus kidney transplantation, it can be argued that medication adherence is equally important within this patient population.  Lung transplant recipients have a much lower 5-year survival versus kidney transplant recipients, with only 55% of patients surviving that long after transplantation.  Additionally, 35% of lung transplant recipients have at least one episode of acute cellular rejection within the first year.46 Furthermore, the result of graft loss in lung transplantation certainly means death as compared to in kidney transplant patients who are able to resume dialysis after graft loss.  
In large study (N=7,284 lung transplant recipients) of the UNOS database conducted by Castleberry et al47, the authors observed both early (<1 year after transplant) and late (2-4 years after transplantation) non-adherence.  The survival for recipients with early non-adherence was much shorter versus controls (2.25 vs. 5.67 years, p<0.001).  Additionally, recipients who had late non-adherence had shorter survival versus the control group (5.6 vs. 7.4 years, p<0.001).  Again, this demonstrates the critical importance for not only immunosuppression adherence at all phases post-transplantation, but particularly within the first year.  Although this study is large and well powered, there are many limitations as the data is extracted from a national registry.  The UNOS database does not require clinicians to report non-adherence status.  Thus, recipients who were non-adherent and did not have adverse effects were not well represented.  Additionally, the clinicians did not report the non-adherence status based on a consistent or sensitive measure across centers.  Additionally, it has been shown that non-adherence after lung transplantation increases the risk of a form of chronic rejection known as bronchiolitis obliterans syndrome (BOS).47  This is an important and likely explanation for decreased survival in the study by Castlebury et al.   Furthermore, BOS is a major cause of death in lung transplant recipients after one year post-transplant.46
Similar findings in lung and kidney transplant recipients have also been observed after liver and heart transplantation.49-51  The body of evidence presented above reflects the need for a standardized way to measure adherence and provide intervention to recipients who are non-adherent.  Additionally, healthcare professionals should identify transplant candidates who are at risk for immunosuppression non-adherence after transplantation.  The next section of this review will focus on the various medication adherence tools that may be useful in evaluating immunosuppression adherence during the post-transplant period.  
1.5	TECHNIQUES AND TOOLS TO EVALUATE MEDICATION ADHERENCE
	Despite immunosuppression adherence being such a vital part of clinical outcomes after transplantation, there has been almost no standardization in measurement.  There exist both direct and indirect measurements of medication adherence.52 Direct measurements involve clinicians directly observing patients taking their medications or measuring drug levels and other biomarkers that may be available in the blood or the tissues.  The primary problem with direct measurement is that it is very costly and time consuming for healthcare professionals.  It is simply not feasible for each clinician to observe all of their patients taking medications.  Additionally, measurement of drug levels or biomarkers could be misleading if a patient is primarily non-adherent, but takes double doses of their medications directly prior to their physician visit.  This phenomenon has been described as “white coat adherence.”  Indirect measurements include pill counts, rates of prescription refills, electronic medication monitors, patient diaries, or questionnaires for patient caregivers, if the patient is a patient.  Pill counts and prescription refills are not necessarily reflective of the ingestion of the medication by the patient as they may refill the prescription, but not take or throw the pills away.  Patient diaries are also easily altered by the patient.  Possibly the most useful approach in clinical is the clinician-administered questionnaire due to its inexpensiveness and simplicity.  Proposed medication adherence assessments tools must be able to illicit and detect even minor deviations in immunosuppression adherence.  The tool should also be easy to interpret and score so that it can be conducted rapidly in clinical practice.  Lastly, the tool should be reliable, valid, and responsive to change over time.53  Table 2 provides different ways to assess construct measurements of a proposed medication tool as adapted from Kimberlin et al.54

Table 2. Components of reliability, validity, and responsiveness within a medication adherence instrument

Reliability represents the “true” score with as little error as possible.  It incorporates the following:Stability is the ability of the instrument to produce the same result in the same individual at two time points.Internal consistency is used to measure if questions measuring the same construct on the questionnaire correlate.Interrater reliability is the equivalence of various observers using the tool to obtain the same result.  Validity represents how well the instrument measures what it purports to measure.  Content validity addresses how well the instrument items represent all items that could be used to measure a given construct.Criterion-related validity provides evidence regarding how well the instrument’s scores on the new measure correlate to constructs that should be related.Construct validity states that results of the new measurement should relate to variables that are known to be associated with the intended construct based on existing evidence.Responsiveness reflects the ability of the instrument to detect changes over time in a given construct of interest
*Adapted from Kimberlin CL, Winterstein AG. Validity and reliability of measurement instruments used in research. Am J Health Syst Pharm 2008; 65: 2276.

As there is no gold-standard assessment tool amongst the methods described above, it has been postulated and shown that composite score of adherence including patient self-report, healthcare professional assessment, and drug level monitoring could provide the highest sensitivity and specificity to identify immunosuppression non-adherence.  In fact, one study found that a composite score for immunosuppression non-adherence was superior to using electronic monitoring via an immunosuppression refill counter.55  Electronic monitoring may lack sensitivity as patients are able to refill medications on-time despite hoarding unused or untaken medications at home.  The investigators of this study also noted that the composite score for immunosuppression non-adherence works best when more than one physician or healthcare professional evaluates the patient.  
2.0 	MEDICATION ADHERENCE ASSESSMENT TOOLS FOR TRANSPLANTATION





Table 3. Components, validity, and reliability of medication assessment instruments
Scale	Taking?	Timing? 	Reliability	Validity
VAS57	Yes	No	NA	Convergent validity established
Brief Antiretroviral Compliance Index58-60	Yes	Yes	Excellent	Construct and convergent validity established
Immunosuppressive Therapy Compliance Instrument61	Yes	No	NA	Construct validity established
Adherence Questionnaire Rheumatology62	Yes	No	Moderate	Questionable validity
Interview to verify adherence with antihypertensive therapy63	Yes	No	NA	NA
Nine-item questionnaire64	Yes	No	NA	Predictive validity
Euan Heart Failure Self-care Behavior Scale65	Yes	No	NA	Content and construct validity established
Adapted version 4 of the Medication Adherence Report Scale66	Yes	No	Good	Construct validity established
Morisky Medication Adherence Scale67	Yes	No	Good	Construct and content validity established
Medication Adherence Self-Report Inventory68	Yes	Yes	Good	Validity established in HIV and Lupus patients
Basel Assessment of Adherence Immunosuppression Scale55,69	Yes	Yes	Good	Predictive validity established
*Adapted from Dobbels F, Berben L, De Geest S, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: A systematic review.  Transplantation. 2010; 90: 205-219.  

Although the above table is not inclusive for all medication assessment instruments, one can conclude that significant heterogeneity exists between measurements.  These instruments also demonstrate that most scales have not been assessed for reliability or validity amongst its constructs.  Additionally, many of these scales have been validated or implemented in patient populations that have specific disease states such as HIV, heart failure, or hypertension.  Thus, the transition to using these instruments in transplant recipients may be less straightforward.  Out of the referenced instruments above only the Basel Assessment of Adherence Immunosuppression Scale (BAASIS), the Brief Antiretroviral Adherence Index (AACTG), and the Medication Adherence Self-Report Inventory (MASRI) have assessed validity and reliability and also whether the patient is taking their medications on-time.  After reviewing these three scales, only the BAASIS scale has been used in transplant recipients.  
2.1	INTERVENTIONAL METHODS TO IMPROVE IMMUNOSUPPRESSION ADHERENCE IN TRANSPLANTATION
There have been numerous studies evaluating immunosuppression adherence interventions after solid organ transplantation.70 Interventions can come in many shapes and sizes and are certainly not uniform between studies, health systems, and individual patients.  Table 4 outlines the various types of medication intervention classifications at both the intervention and patient level.  The efficacy of interventions are often difficult to evaluate because they do not use the same definition of adherence and some have not been studied using the randomized controlled trial design.71,72  Typically, most studies have also included a small number of transplant recipients often allowing for inadequate power.  




Educational/Cognitive	Information, knowledge or education delivered to the patient verbally, written, or via computer
Counseling/Behavioral	Targeted to shape and reinforce patient behavior and focuses on patient empowerment
Psychologic/Affective	Targeted to the feelings and emotions or social supports of the patient
Level of the Intervention
Patient	Patient-level only intervention
Micro level	Strategies focused on the patient-provider interaction
Meso level	Strategies to improve the treatment team at a particular hospital
Macro Level	Focused on the healthcare system of the environment in which the patient lives
*Adapted from De Bleser LD, Matteson M, Dobbells F, Russell C, De Geest S. Interventions to improve medication-adherence after transplantation: a systematic review.  Transplant Int. 2009; 22: 780-797.

	There are numerous health professionals situated to carry out these interventions within an interdisciplinary transplant team.  Interventionists that were utilized in various studies included pharmacists, nurse specialists, nurse practitioners, or other members of the transplant team.  Previous medication interventions have incorporated variable lengths of follow-up, including some as short as 5 days or follow-up out to 12 months.70  The majority of the interventions that have been trialed incorporate a mixed approach at the patient level. 




















3.0 	A PHARMACIST-GUIDED INTERVENTION TO IMPROVE IMMUNOSUPPRESSION ADHERENCE
	Transplant pharmacists are an integral part to any transplant center.  They are able manage dosing, drug interactions, insurance coverage issues, and develop protocol amongst other responsibilities.  Transplant pharmacists reduce economic burden after transplantation by preventing drug interactions and improving immunosuppression adherence.  Additionally, pharmacists established a role in the pre-transplant evaluation period through assessing medication adherence, recommending vaccinations, and providing education to patients and their family members regarding their post-transplant medication regimens.75  The evolution of the transplant pharmacist has been validated and further justified by the changes in the UNOS bylaws and as described by the Centers for Medicare and Medicaid Services (CMS).  UNOS bylaws have been updated in 2004 to include the transplant pharmacy specialist as a necessary part of the transplant multidisciplinary team.  Furthermore, CMS has outlined expectations for transplant centers to include a pharmacology expert as a vital component of the transplant team.75,76  Thus, transplant pharmacists are ideally positioned to provide a meaningful medication adherence intervention that could have lasting impact as pharmacists follow patients after their transplant.  A pharmacist-guided intervention could dramatically impact public health outcomes by increasing allograft longevity and decrease the need for retransplantation during a time where allocated organs are already a scarce resource.  




Figure 3. Timeline and activities of the lung transplant pharmacist at a single institution
	
The proposed intervention will utilize the pharmacist in pre- and post-transplant care.  In the first phase of the study, the pharmacist will assess and score the pre-transplant candidates medication adherence during clinic evaluation.  The adherence assessment will use all three of the validated tools mentioned Section 2.0 (BAASIS, AACTG, MASRI).  The specific aims of the proposed project are outlined in Table 5.

Table 5. Specific aims of a pharmacist-guided intervention to improve medication adherence in lung transplant recipients

To evaluate the relationship between health determinants incidence of non-adherence during the first post-transplant year in lung-transplant recipients.To determine the impact of a pharmacist-guided medication adherence intervention during the first post-transplant year in lung-transplant recipients at high risk for non-adherence.

	Aim 1 will be carried out via a prospective study utilizing the pharmacist in the pre- and post-transplant phase.  The study will aim to enroll 150 pre-lung transplant candidates in order to evaluate a minimum of 75 post-lung transplant recipients during their first year after transplantation.  This aim also assumes that 20% of lung transplant recipients will be non-adherent with their immunosuppression after transplantation.  Upon consenting the patient in pre-transplant clinic, the pharmacist will administer, evaluate, and record adherence results with adapted versions of the BAASIS, MASRI, and AACTG scales.  These scales will be modified in order to better suit the pre-transplant phase of the assessment.  Patient educational, marital, and socioeconomic status will also be assessed and recorded.  Additionally, pre-transplant candidates’ trust in the healthcare system will be evaluated. After transplantation occurs, a pharmacist will follow-up with the lung transplant recipient at 6 and 12 months from their index surgery date via a phone or clinic encounter.  During these visits, pharmacists re-administer medication adherence assessments using the same three scales.  Additionally, information regarding dose-normalized calcineurin inhibitor levels will be recorded in order to correlate dose-normalized levels to adherence instrument results.  Post-transplant acute cellular rejection episodes, antibody-mediated rejection episodes, infectious complications, and chronic lung allograft dysfunction will all be documented for the purposes of evaluating these outcomes between adherence groups.  Baseline characteristics will be assessed with descriptive statistics and normality will be assessed using the Shapiro-Wilk Test for normality.  Multivariable log-binomial regression modeling will be used to evaluate health determinant risk factors for immunosuppression non-adherence after transplant.  Acute cellular rejection burden after transplantation will be assessed with a composite rejection standardized score (CRSS).77,78  Mixed linear modeling will be used in order to predict CRSS based on transplant characteristics and adherence scores over the different time points.  
	Aim 2 will also be carried out in a prospective fashion over a 2-year period after transplantation.  Based on results from the first study, the pharmacist will screen pre-transplant candidates for eligibility based on one of the three validated adherence instruments (MASRI, BAASIS, or AACTG).  High-risk patients will be enrolled based on health determinants and instrument scores from the first model.  Patients will then be randomized to either a control or pharmacist-intervention arm.  The pharmacist-intervention arm will incorporate clinical teaching regarding immunosuppression during the initial inpatient transplant stay.  Clinical teaching will also incorporate feedback in order to stimulate a behavioral change in patients who are at risk for being non-adherent.  Pharmacists will also follow-up with recipients in the intervention arm at 3 month intervals.  Recipients in the control arm will follow standard of care procedures, but will still be assessed via the selected instrument at 3 months intervals.  The primary outcome will be burden of acute cellular rejection as assessed by the CRSS.  
4.0 	CONCLUSION
Immunosuppression non-adherence after solid organ transplantation is a complex problem that lacks a standardized approach for measurement and validated intervention.  Medication non-adherence after transplantation is a prevalent concern that requires public health intervention in order to reduce economic costs and improve allograft survival.  In a time where organs are scarce resources, clinicians and healthcare professionals must do everything they can to ensure allograft longevity.  This means ensuring patients are empowered and motivated to adhere to their medication regimens.  Lastly, transplant pharmacists are ideally situated to be the champions in improving medication adherence after solid organ transplantation.
The public health significance of immunosuppression non-adherence after solid organ transplantation cannot be understated.  Non-adherence is a complex problem that requires interdisciplinary collaboration and a public health lens in order to understand contributing risk factors and psychosocial behaviors.  Through improved understanding of immunosuppression non-adherence, healthcare professionals can construct reliable and valid methods for adherence measurement after transplantation.   Currently, organs are a scarce resource with many more patients on waiting lists than receiving transplants.  Thus, the longevity of the organs being transplanted must be optimized in order to reduce the need for retransplantation. Through proper and rigorous study design, immunosuppression adherence interventions can improve upon these outcomes.  
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